Vision Marine Technologies Secures CE Certification for E-Motion™ Electric Boat

Vision Marine Technologies Achieves European CE Certification

MONTRÉAL, QC (FreePR.org) -- Vision Marine Technologies Inc. (referred to as "the Company", "Vision Marine", "we", "us", "our") (Nasdaq:VMAR), a pioneer in electric marine propulsion technologies, is thrilled to announce that one of our vessels equipped with the innovative E-Motion™ 180E Electric Marine HV Powertrain has successfully obtained CE certification, signifying conformity with European standards. This achievement underscores Vision Marine's strategic ambitions to enhance its presence in the European market for electric marine propulsion, tailored to meet increasing demand for sustainable and high-performance boating solutions.

Obtaining CE certification is a significant advancement in Vision Marine's European strategy. Following several successful integrations of the E-Motion™ 180E system into boats from European manufacturers, acquiring CE certification for this initial vessel was a natural next step to comply with the stringent regulatory standards in the region.

The European marine sector is rapidly adopting electric propulsion, driven by a strong commitment to sustainability and supportive regulations. According to market research, the global electric boat market is projected to grow from $3.3 billion in 2023 to $7.7 billion by 2030, representing a Compound Annual Growth Rate (CAGR) of 13.0% (MarketsandMarkets). Europe's specific market, valued at approximately $2.09 billion in 2022, is anticipated to reach $4.4 billion by 2028 at a CAGR of 13.2% (Business Market Insights). Vision Marine is well-positioned to align with this market evolution, positioning its state-of-the-art E-Motion™ system as a crucial asset for manufacturers eager to adapt to these changing demands.

This milestone highlights the critical importance of the European market for Vision Marine Technologies, reflecting the accelerating adoption of electric propulsion and the immense potential for innovative solutions. Securing CE certification reduces significant obstacles for manufacturers, affirming Vision Marine's capacity to offer advanced and reliable electric systems designed for European standards. By synchronizing its engineering excellence with the region's dynamic needs, Vision Marine is ideally positioned to assist manufacturers in delivering next-generation marine products and seizing opportunities within the expanding global electric boating sector. This achievement also exemplifies Vision Marine's dedication to driving sustainable innovation and fostering long-term growth in the European market through its electric propulsion solutions.

We believe this milestone validates the performance, reliability, and compatibility of our E-Motion™ 180E Electric Marine HV Powertrain system, likely encouraging manufacturers to integrate Vision Marine's innovative electric propulsion solutions into their offerings.

"Achieving CE certification is a pivotal moment for Vision Marine as we advance our footprint in the European market," remarked Alexandre Mongeon, CEO of Vision Marine. "This accomplishment highlights our commitment to delivering top-tier electric powertrain systems that adhere to the highest safety and performance standards. As we expand in Europe, we remain devoted to pushing the boundaries of electric marine innovation in the American market as well."

About Vision Marine Technologies Inc.

Vision Marine Technologies, Inc. (NASDAQ: VMAR) is revolutionizing the marine sector with its cutting-edge E-Motion™ outboard powertrain system. By leveraging advanced battery technology, high-efficiency motors, proprietary software, and innovative assembly techniques, Vision Marine is leading the charge towards sustainable, electric-powered recreational boating.

Forward-Looking Statement

This press release contains forward-looking statements protected by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements, whether expressed or implied, are based solely on information available to us at the time and are valid only as of the date made. Investors can identify many (but not all) of these statements by terms such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may," or similar expressions in this release. These statements involve risks, uncertainties, and other factors that may lead to actual results differing materially. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that such expectations will hold true, and urges investors to closely examine the risks detailed in Vision Marine's Annual Report on Form 20-F for the year ending August 31, 2024, and other periodic filings with the SEC. Vision Marine does not assume any obligation to update or revise forward-looking statements, except as required by law.

Investor and Company Contact:

Vision Marine Technologies

Bruce Nurse

(303) 919-2913

bn@v-mti.com

Website: visionmarinetechnologies.com

Twitter: @marine_vision

Facebook: @VisionMarineTechnologies

###

Sponsor Message

Millions of Americans depend on Canadian pharmacies for reasonably priced medications like Lipitor and Crestor for cholesterol, or Nexium for acid reflux and GERD management. Diabetes patients depend on insulin like Humalog and Lantus, while asthma and COPD sufferers use Advair Diskus and Ventolin inhalers. Mental health medications such as Zoloft, Prozac, and Abilify provide critical support for those battling depression, anxiety, or bipolar disorder, while blood thinners like Eliquis, Plavix, and Xarelto are crucial for preventing stroke and other heart-related complications. Commonly ordered medications include Celebrex for inflammation and pain and Synthroid for thyroid management. Furthermore, popular medications like Viagra and Cialis provide relief for erectile dysfunction, while Januvia helps regulate diabetes. For individuals suffering from narcolepsy or severe sleepiness, Provigil and Nuvigil provide much-needed relief. By offering affordable options like Cymbalta for nerve pain and Aricept for Alzheimer's, Canadian pharmacies serve patients in the United States.